Gynecologic Cancer Treatment Center
Diseases Treated
Endometrial Cancer
Clinical trials for endometrial/uterine cancer
If you're interested in a clinical trial, please contact one of our Gyn Oncology Research Nurses:
Julie Lee, RN (617) 632-4975
Christin Whalen (617) 582-7738
Protocol 05-020: PTK787 Plus Docetaxel for Recurrent Mullerian Malignancies
This is a Phase II study to measure the effectiveness of oral PTK787, a drug that blocks angiogenesis, and docetaxel (taxotere), given weekly intravenously. Another aspect of this study is to test the effect of this drug combination on special MRI scans, called DC-MRI scans.
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma - Endometrial/Uterine Cancer
Rationale
Patients with a diagnosis of early-stage uterine leiomyosarcoma have a 70% chance of relapse or recurrence of their disease.
Purpose
The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remaining (known as adjuvant therapy).
Treatment
Patients enrolled in this trial will receive 4 cycles of gemcitabine and docetaxel followed by 4 cycles of adriamycin. Following completion of chemotherapy, they will have repeat imaging at regular intervals to monitor for disease recurrence along with periodic clinical evaluations.
Medroxyprogesterone in Patients With Endometrioid Adenocarcinoma
Purpose
Phase II trial to study the effectiveness of medroxyprogesterone in treating patients who have endometrioid cancer.
Eligibility
- At least 18 years old
- At least 3 months since hormone therapy
Treatment
Patients will receive an injection of medroxyprogesterone approximately 3 weeks before undergoing surgery to remove the uterus. Some patients will have tissue samples collected before and after receiving medroxyprogesterone and during surgery. Patients will be evaluated every 3 months for 2 years, every 6 months for 3 years, and once a year thereafter.
Oxaliplatin and Gemcitabine followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
Rationale
This research study is a Phase II clinical trial. Phase II trials test the clinical effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
"Investigational" means that the drug is still being studied and that research doctors are trying to find out more about it, such as the safest dose to use, the side effects it may cause, and whether the drug is effective for treating different types of cancer. It also means that the U.S. Food and Drug Administration (FDA) has not yet approved the combination of gemcitabine and oxaliplatin with radiation therapy to treat your type of cancer.
Treatment
If you are eligible and choose to participate in the study, you will begin study treatment. The following tests and procedures will be performed on this trial:
Medication: Each treatment cycle lasts 4 weeks, during which time you will receive both oxaliplatin and gemcitabine the first and third week. During the second and fourth week you will not receive the study medication. After 3 cycles of chemotherapy treatment, you will get radiation therapy 5 days a week for 5 weeks.
Physical Exams: At the start of each cycle, you will have a physical exam and you will be asked questions about your general health, and specific questions about any problems you might be having and any medications you may be taking.
Prior to each chemotherapy treatment you will also have the following:
- Blood tests, including chemistry and blood counts
- Neurology exam
After 3 cycles of chemotherapy you will have:
- An assessment of your tumor by x-ray, CT scan, or MRI
- After the final radiation treatment a CT scan will be done about every 3 months for up to 2 years.
More endometrial cancer clinical trials
Please continue to check this site for updates. New trials are added all the time.
Entering a Clinical Trial; Is it Right for You?
